

Jaydess[®] Levonorgestrel 13.5mg intrauterine system (IUS) for contraception

NHS Devon

Commissioning policy

The use of Jaydess[®] levonorgestrel 13.5mg IUS is accepted in Devon for prevention of pregnancy. The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

The National Institute for Health and Care Excellence (NICE) clinical guidance on long-acting reversible contraception recommends women requiring contraception should be given information about and offered a choice of all methods, including long-acting reversible contraception.

The efficacy of Jaydess[®] has been established in clinical trials; it is an alternative treatment option to Mirena[®] for women who require a long-acting reversible contraceptive. There have been no direct comparisons between the versions of the two products currently available.

Jaydess[®] offers reversible contraception for up to 3 years. There is no evidence of a major advantage in terms of efficacy, safety or user acceptability over Mirena[®] which offers reversible contraception for up to 5 years.

Jaydess[®] is available at a lower acquisition cost compared to Mirena[®] when contraception is required for up to 3 years. Where contraception for a longer period is required, Mirena[®] is the more cost-effective option.

In clinical trials, at 3 years half as many women had become amenorrhoeic with Jaydess[®] as had done with Mirena[®] and women may be more likely to continue with light regular bleeds with Jaydess[®].

It was considered appropriate that Jaydess® should be an option available so that women can chose a method of contraception which best suits their needs.

Guidance notes on exceptionality

Not applicable.

Date of publication:	Version:
30.03.2015	Policy agreed by Northern, Eastern and Western Devon CCG and South Devon and Torbay CCG Policy adopted by NHS Devon CCG on 01.04.2019 Policy adopted by NHS Devon ICB on 01.07.2022